Sponsor: 
Merck Sharp & Dohme (Australia)
Administration route: 
Intramuscular injection, Subcutaneous injection
Vaccine group: 
Combination vaccines

Registered for use in children aged 12 months to 12 years.

MMRV — measles-mumps-rubella-varicella combination vaccine

Lyophilised powder in a monodose vial with a pre-filled diluent syringe.

Each 0.5 mL reconstituted dose contains:

  • ≥103.00 culture infectious dose 50% (TCID50) of live attenuated measles virus (Enders’ attenuated Edmonston strain)
  • ≥104.30 TCID50 of live attenuated mumps virus (Jeryl Lynn B level strain)
  • ≥103.00 TCID50 of live attenuated rubella virus (Wistar RA 27/3 strain)
  • ≥103.99 plaque-forming units of live attenuated varicella-zoster virus (Oka/Merck strain)
  • 20 mg sucrose
  • 11 mg hydrolysed porcine gelatin
  • 2.5 mg urea
  • 16 mg sorbitol
  • 0.38 mg monosodium L-glutamate
  • 0.25 mg recombinant human albumin
  • 5 µg neomycin
  • residual components of MRC-5 cells
  • 0.5 µg bovine serum albumin

For full details, refer to the product information and consumer medicine information sheets for ProQuad vaccine available on the TGA website.

Page history

Last updated: 
12 April 2019
Last reviewed: 
12 April 2019

Definitions

MMRV
measles-mumps-rubella-varicella